Eli Lilly and Co (XSGO:LLYCL) Cyclically Adjusted FCF per Share: CLP (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSGO:LLYCL Eli Lilly and Co XSGO:LLYCL
73 GF Score
Price CLP1,104,400.00
GF Value CLP1,439,146.26
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted FCF per Share?

Eli Lilly and Co XSGO:LLYCL 73 Cyclically Adjusted FCF per Share is CLP as of Jun. 2026. GuruFocus rates XSGO:LLYCL with a GF Score™ of 73/100 and a GF Value™ of CLP1,439,146.26 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share for the three months ended in Jun. 2026 was CLP7,868.905. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is CLP for the trailing ten years ended in Jun. 2026.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted FCF Growth Rate was 41.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Eli Lilly and Co was 17.20% per year. The lowest was -6.20% per year. And the median was 4.80% per year.

As of today (2026-09-20), Eli Lilly and Co's current stock price is CLP1104400.00. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was CLP. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Eli Lilly and Co was 279.06. The lowest was 16.39. And the median was 60.15.


Eli Lilly and Co  (XSGO:LLYCL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Eli Lilly and Co was 279.06. The lowest was 16.39. And the median was 60.15.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Eli Lilly and Co Cyclically Adjusted FCF per Share Related Terms


Eli Lilly and Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted FCF per Share Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XSGO:LLYCL vs JNJ, ABBV, MRK: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.


XSGO:LLYCL
73GF Score
Eli Lilly and Co XSGO:LLYCL
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7868.905/333.9520*333.9520
=7,868.905

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 882.525 241.428 1,220.741
201612 1,039.234 241.432 1,437.482
201703 106.061 243.801 145.279
201706 899.764 244.955 1,226.666
201709 965.454 246.819 1,306.282
201712 720.636 246.524 976.204
201803 114.689 249.554 153.476
201806 732.643 251.989 970.946
201809 1,251.461 252.439 1,655.560
201812 731.848 251.233 972.811
201903 72.932 254.202 95.813
201906 602.075 256.143 784.968
201909 980.833 256.759 1,275.714
201912 1,466.579 256.974 1,905.901
202003 109.524 258.115 141.703
202006 2,003.166 257.797 2,594.915
202009 1,100.654 260.280 1,412.193
202012 1,051.253 260.474 1,347.805
202103 1,109.214 264.877 1,398.476
202106 1,086.344 271.696 1,335.267
202109 1,266.446 274.310 1,541.804
202112 1,938.522 278.802 2,321.982
202203 1,902.359 287.504 2,209.697
202206 505.012 296.311 569.165
202209 1,838.559 296.808 2,068.645
202212 989.095 296.797 1,112.916
202303 953.438 301.836 1,054.886
202306 -106.309 305.109 -116.359
202309 1,207.308 307.789 1,309.933
202312 -1,202.623 306.746 -1,309.286
202403 188.489 312.332 201.536
202406 247.096 314.175 262.650
202409 2,424.093 315.301 2,567.485
202412 1,094.701 315.605 1,158.339
202503 166.957 319.799 174.346
202506 1,459.600 322.561 1,511.145
202509 7,222.750 324.800 7,426.268
202512 451.086 324.054 464.864
202603 2,975.592 330.213 3,009.285
202606 7,868.905 333.952 7,868.905

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of CLP mean?
Eli Lilly and Co (XSGO:LLYCL) has a Cyclically Adjusted FCF per Share of CLP as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Cyclically Adjusted FCF per Share too high?
Eli Lilly and Co's current Cyclically Adjusted FCF per Share is CLP. Overall, Eli Lilly and Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cyclically Adjusted FCF per Share compare to JNJ and ABBV?
Eli Lilly and Co's Cyclically Adjusted FCF per Share of CLP can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Cyclically Adjusted FCF per Share is CLP. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSGO:LLYCL) is currently considered Modestly Undervalued. The stock's GF Value™ is CLP1,439,146.26, compared to a current price of CLP1,104,400.00 — trading 23.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is CLP. Eli Lilly and Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Eli Lilly and Co (XSGO:LLYCL), the current Cyclically Adjusted FCF per Share is CLP as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSGO:LLYCL) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CLP1,104,400.00 is trading 23.3% below its estimated GF Value™ of CLP1,439,146.26. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSGO:LLYCL:

  • Cyclically Adjusted FCF per Share: CLP
  • GF Value™: CLP1,439,146.26 vs. price of CLP1,104,400.00 (23.3% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the XSGO:LLYCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
73GF Score

Get the complete analysis for XSGO:LLYCL

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CLP1,104,400.00
Price
CLP1,439,146.26
GF Value